Nectar Lifesciences share news, announcements and annual reports
NSE: NECLIFEBSE: 532649Pharmaceuticals & BiotechnologySmall Cap
Nectar Lifesciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2005
Last close ₹10.33down ₹0.01 (0.10%)BSE ₹10.31
Share price at the NSE close on 29 Oct 2026. Previous close ₹10.34.
29 Oct: open ₹10.36, high ₹10.49, low ₹10.20
52-week range of traded prices to 29 Oct 2026
₹9.30Low, 30 Mar 2026₹22.40High, 23 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹201 Cr2,221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.34
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −31.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹171 crore of one-off items, the largest of them in the quarter to Sep 2025.
- −9.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −15.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 44,04072.5% delivered
Nectar Lifesciences board and management
56 filed, newest first. Page 2 of 2.
Sep 2007
10 Sep · Management
The Board of Directors in their meeting held on today i.e. 3rd September, 2007 have appointed Smt. Raman Goyal as a Wholetime Director of the company for a period of Five Years w.e.f. 01.09.2007, subject to the approval of members in their forthcoming Annual General Meeting
Aug 2007
2 Aug · Management
The Board of Directors in their Meeting held on today i.e. 30.07.2007 have appointed Mrs. Raman Goyal on the Board as an additional director of the company who shall hold the office upto the date of next Annual General Meeting. She belongs to the promoters group of the company
Jun 2007
12 Jun · Management
Board of Directors vide resolution dated May 31, 2007 have reappointed Sh. Sanjiv Goyal as a Chairman & Managing Director of the company for a period of Five Years w.e.f. 01.06.2007, subject to the approval of members in their General Meeting. Further the Company is sending to its members the abstract of terms of re-appointment of Sh. Sanjiv Goyal, as per the provisions of Section 302 of the Companies Act, 1956. Further the Company has submitted a copy of the abstract. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
7 May · Management
The Board of Directors in their Meeting held on today i.e. 28.04.2007 have appointed Mr. Basant Kumar Goswami I.A.S. (retd.) on the Board as an additional director (Independent director) of the company who shall hold the office upto the date of next Annual General Meeting
Apr 2007
2 Apr · Management
Mrs. Raman Goyal has resigned from the Directorship of the Company and hence also ceased to be a whole time director of the Company.
Feb 2007
12 Feb · Management
Mr. V.D. Aggarwal has resigned from the Directorship of the Company